A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis of stage 2 (S2) following crossover

被引：0
|
作者：
Cupissol, Didier
Seiwert, Tanguy Y.
Fayette, Jerome
Ehrnrooth, Eva
Blackman, Alice Sarah
Cong, Xiuyu Julie
Cohen, Ezra E. W.
机构：
[1] Ctr Val dAurelle, Montpellier, France
[2] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[3] Ctr Leon Berard, F-69373 Lyon, France
[4] Boehringer Ingelheim GmbH & Co KG, Copenhagen, Denmark
[5] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6001
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial
    Gulati, Shuchi
    Crist, McKenzie
    Riaz, Muhammed Kashif
    Takiar, Vinita
    Lehn, Maria
    Monroe, Ilaina
    Palackdharry, Sarah
    Kurtzweil, Nicky
    Jandarov, Roman
    Harun, Nusrat
    Wise-Draper, Trisha M.
    CLINICAL CANCER RESEARCH, 2023, 29 (10) : 1906 - 1915
  • [12] Phase II study of temsirolimus and erlotinib in patients (pts) with recurrent/metastatic (R/M), platinum-refractory head and neck squamous cell carcinoma (HNSCC)
    Bauman, Julie E.
    Arias-Pulido, Hugo
    Lee, Sang-Joon
    Considine, Michael
    Fekrazad, M. Houman
    Howard, Jason
    Bishop, Justin A.
    Olson, Garth T.
    Jones, Dennie V.
    Fertig, Elana J.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [13] An open-label, non-randomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of the interim safety analysis.
    Sacco, Assuntina Gesualda
    Messer, Karen
    Natsuhara, Amanda
    Chen, Ruifeng
    Wong, Deborah J. L.
    Worden, Francis P.
    Adkins, Douglas
    Pittman, Emily
    Zhang, Jing
    Daniels, Gregory A.
    Gold, Kathryn A.
    Espiritu, Maechelle
    Sutton, Brian
    Cohen, Ezra E. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [14] A phase II clinical trial of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
    Ji, D.
    Sang, Y.
    Liu, X.
    Guo, Y.
    Yang, Y.
    Chen, G.
    Dong, S.
    Wang, Y.
    He, X.
    Ying, H.
    Lu, X.
    Wang, Y.
    Hu, C.
    Ji, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S626 - S626
  • [15] Efficacy of cetuximab based chemotherapy after immunotherapy treatments (IT) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
    Hernando-Calvo, A.
    Mirallas, O.
    Marmolejo, D.
    Felip, E.
    Garralda, E.
    Villacampa Javierre, G.
    Feliu, B.
    Martinez, S.
    Gutierrez, R.
    Dienstmann, R.
    Brana, I.
    ANNALS OF ONCOLOGY, 2019, 30 : 59 - 59
  • [16] Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.
    Chung, Christine H.
    Bonomi, Marcelo Raul
    Steuer, Conor Ernst
    Schell, Michael J.
    Li, Jiannong
    Johnson, Matthew
    Masannat, Jude
    Hernandez-Prera, Juan C.
    McMullen, Caitlin
    Wadsworth, J.
    Patel, Krupal
    Kish, Julie Ann
    Muzaffar, Jameel
    Kirtane, Kedar
    Rocco, James William
    Saba, Nabil F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [17] A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
    Kochanny, Sara E.
    Worden, Francis P.
    Adkins, Douglas R.
    Lim, Dean W.
    Bauman, Julie E.
    Wagner, Stephanie A.
    Brisson, Ryan J.
    Karrison, Theodore G.
    Stadler, Walter M.
    Vokes, Everett E.
    Seiwert, Tanguy Y.
    CANCER, 2020, 126 (10) : 2146 - 2152
  • [18] Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Safety results of a phase I/II study
    Chung, Christine
    Bonomi, Marcelo
    Steuer, Conor
    Schell, Michael
    Li, Jiannong
    Johnson, Matthew
    McMullen, Caitlin
    Wadsworth, J. Trad
    Patel, Krupal
    Kish, Julie
    Muzaffar, Jameel
    Kirtane, Kedar
    Rocco, James
    Saba, Nabil
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [19] Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study
    Adkins, Douglas
    Mehan, Paul
    Ley, Jessica
    Siegel, Marilyn J.
    Siegel, Barry A.
    Dehdashti, Farrokh
    Jiang, Xuntian
    Salama, Noha N.
    Trinkaus, Kathryn
    Oppelt, Peter
    LANCET ONCOLOGY, 2018, 19 (08): : 1082 - 1093
  • [20] A Phase II Trial of Personalized Immunotherapy in Patients (pts) with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M HNSCC) That Have Progressed on Prior Immunotherapy
    Zandberg, D. P.
    Chen, J.
    Tatsuoka, C.
    Normolle, D. P.
    Ohr, J.
    Isett, B.
    Rahman, Z.
    Fenton, M.
    Gooding, W.
    Vujanovic, L.
    Bao, R.
    Marsh, C.
    Seastone, D.
    Gorantla, V.
    Pabla, S.
    Conroy, J.
    Ferris, R. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E4 - E4
12345